DHEA in Men Over 40: What the Hormone Does and What the Supplement Does Not

Dehydroepiandrosterone is the most abundant circulating steroid hormone in the human body, it declines more steeply with age than testosterone does, and it sits on the shelf of every supplement store in the United States at 25 milligrams a capsule. Those three facts together have built a large industry on a small assumption, which is that restoring a hormone that falls with age restores what fell with it. The randomized evidence in older men does not support that assumption, and the reason it does not is more interesting than a simple negative result. Here is what DHEA and DHEA-S actually measure, where the age curve comes from, why the conversion math works differently in men than in women, and what a raised or suppressed reading is genuinely worth knowing.

Dehydroepiandrosterone, almost always written as DHEA, is a steroid hormone produced mainly by the zona reticularis of the adrenal cortex, with a small additional contribution from the testes. By concentration it is the most abundant circulating steroid in the human body, present at levels hundreds of times higher than testosterone. It is also a precursor rather than an end product, meaning its biological role is largely to be converted into something else, principally androstenedione and from there into testosterone or estradiol inside peripheral tissues.

The reason DHEA attracts attention in men over 40 is the shape of its age curve. Adrenal DHEA output peaks in the early twenties and then falls steadily for the rest of life, a pattern distinct enough that endocrinologists gave it a name, adrenopause. A 70 year old man typically carries somewhere between 10 and 20 percent of the DHEA sulfate he carried at 25. Nothing else on a standard hormone panel drops that far. Total testosterone in a healthy man declines by roughly 1 percent a year, which over the same span produces a much shallower slope.

Laboratories measure DHEA sulfate rather than DHEA because the sulfated form is stable enough to interpret from a single blood draw. The adrenal gland secretes both, and an enzyme called sulfotransferase converts freely between them. Unsulfated DHEA has a circulating half life of roughly 15 to 30 minutes and rises and falls with the same adrenocorticotropic hormone rhythm that drives cortisol, so a sample taken at 7 in the morning and a sample taken at 4 in the afternoon can differ by more than any supplement would change it. DHEA sulfate persists for several hours, circulates at concentrations several hundred times higher, and stays essentially flat across the day.

That stability is why DHEA-S ended up as the standard marker, and it also creates a common source of confusion on lab reports. A man who orders DHEA and a man who orders DHEA-S receive numbers in different units and different ranges that are not interchangeable. DHEA-S is reported in micrograms per deciliter and typically runs in the hundreds for a young man. Unsulfated DHEA is reported in nanograms per deciliter and runs an order of magnitude lower. Comparing a result to a reference range printed for the other analyte is one of the more frequent misreadings of a hormone panel.

This curve represents the central tendency described across population reference data rather than measurements from a single cohort, and individual variation around it is wide enough that two healthy men of the same age can differ threefold. The shape is the point worth carrying. The decline is close to linear across decades rather than a cliff at any particular birthday, which is why a man in his forties comparing his result to a laboratory reference range built from adults of all ages will usually be told he is normal while sitting at roughly half of what he carried in his twenties.

Oral DHEA does not meaningfully raise testosterone in men, and the reason is arithmetic rather than pharmacology. In an adult male, the testes produce the overwhelming majority of circulating testosterone directly, and adrenal precursors including DHEA contribute under 5 percent of the total. Adding precursor to a pathway that supplies a twentieth of the output cannot move the output much. In women the situation is reversed, because a substantial fraction of female androgen exposure originates from adrenal precursors, which is why the same dose that does nothing in a man produces measurable androgenic effects in a postmenopausal woman.

The conversions that do occur go somewhere, and in men they go disproportionately toward estrogen. DHEA converts to androstenedione, and androstenedione is a substrate for both 17 beta hydroxysteroid dehydrogenase, which produces testosterone, and aromatase, which produces estrone and from there estradiol. Aromatase activity in adipose tissue rises with body fat, so a heavier man converts a larger share of any supplemental precursor down the estrogenic branch. Trials in older men have consistently reported larger proportional increases in estradiol than in testosterone, which is the opposite of what most men buying the supplement expect.

This allocation is a conceptual illustration of relative fate rather than a measured mass balance from a tracer study, and the true proportions shift with body fat, liver function, and dose. The slice worth staring at is the smallest one. The pathway most men are buying DHEA for is the narrowest channel available to it, while the pathway most men are hoping to avoid is roughly three times wider. That asymmetry is structural in male physiology and no dose adjustment changes it.

The most rigorous trial found nothing. Nair and colleagues, publishing in the New England Journal of Medicine in 2006, ran a two year randomized, double blind, placebo controlled study giving 75 milligrams of DHEA daily to elderly men, with a parallel testosterone arm for comparison. DHEA-S was restored into the young adult range and stayed there for the full two years. Body composition, physical performance, insulin sensitivity, and quality of life were unchanged relative to placebo. The duration matters here, because two years of continuous supplementation removes the usual objection that a null result reflects too short an exposure.

Pooled analyses of smaller trials report a slightly less empty picture without contradicting it. Meta-analytic work by Corona and colleagues, published in 2013, found a small reduction in fat mass across placebo controlled trials in older men, with no reliable effect on lean mass, muscle strength, or total testosterone. A modest fat mass signal in pooled data alongside a clean null in the longest and best controlled single trial is the profile of a compound with, at most, a marginal metabolic effect in older men. It is not the profile of a hormone whose restoration reverses features of aging.

Low DHEA-S is better understood as a marker of biological condition than as a cause of it. Observational cohorts including the Rancho Bernardo study and the Massachusetts Male Aging Study have repeatedly found that men with higher DHEA-S live longer and have less cardiovascular disease, and those associations survive adjustment for the obvious confounders. But adrenal androgen output is suppressed by chronic illness, systemic inflammation, prolonged psychological stress, poor sleep, undernutrition, and glucocorticoid medication. A man with a low DHEA-S is frequently a man whose adrenal function is responding to something, and the something is what shortens his life.

This is the standard shape of a confounded biomarker, and DHEA is close to a textbook example. The intervention trials are the test that separates marker from mechanism, and they came back negative. Restoring the number to young adult concentrations for two years produced no measurable benefit, which is difficult to reconcile with a causal role and easy to reconcile with DHEA-S functioning as a readout of adrenal and general health. Treating the readout rather than the condition it reflects is the error the observational data invites and the randomized data forecloses.

DHEA-S earns its place on a panel as a diagnostic input rather than as a treatment target. A markedly elevated result in a man is the finding that carries the most clinical weight, because DHEA-S is almost exclusively adrenal in origin and a high value points toward the adrenal gland rather than the testes. Very high readings prompt evaluation for adrenal tumours and for non classical congenital adrenal hyperplasia, neither of which is diagnosable from an article and both of which belong to a physician. A markedly suppressed result raises the question of adrenal insufficiency, exogenous glucocorticoid exposure, or pituitary disease.

The middle of the range is where interpretation gets unhelpful, and that is where most men over 40 sit. A DHEA-S of 160 in a 48 year old man is entirely expected, tells you nothing that his age did not already tell you, and does not identify a deficiency in any clinical sense. The concept of a DHEA deficiency in an otherwise healthy ageing man is not an established diagnosis, and the age related decline is a normal physiological process rather than a disorder. That distinction is the one most supplement marketing is built on blurring.

DHEA is a hormone sold in the United States under a food regulation, and that mismatch drives most of its practical risks. The Dietary Supplement Health and Education Act permits it to be marketed without premarket approval, and the Anabolic Steroid Control Act of 2004 specifically exempted it while scheduling its chemical relatives. The result is an androgen precursor available in any pharmacy at doses that produce measurable endocrine change, sold without a required conversation about who should not take it. In the United Kingdom, Canada, and Australia it is a prescription medicine, and importing it for personal use is generally not lawful.

Product content is the second practical problem. The analysis by Parasrampuria and colleagues published in JAMA in 1998 examined commercial DHEA products and found actual content varying widely against label claim across brands, and independent testing in the years since has continued to report the same variability. A man taking an unverified 50 milligram capsule may be taking considerably less or considerably more. Reported adverse effects in men include acne, oily skin, scalp hair shedding in those predisposed, breast tenderness reflecting the estrogenic conversion, and mood changes including irritability. DHEA is also prohibited at all times under the World Anti-Doping Agency code, which matters for anyone subject to testing.

Measure DHEA-S once, use it to answer a diagnostic question, and stop treating it as a target. A result in the expected range for your age is information about your adrenal gland working normally, not a deficiency waiting to be corrected. A result far outside that range in either direction is worth a physician appointment, because both adrenal excess and adrenal insufficiency have specific investigations attached to them and neither is managed from a supplement shelf. Everything between those poles is descriptive rather than actionable.

The broader lesson generalises past DHEA. A hormone falling with age, correlating with health in observational cohorts, and being available cheaply over the counter is a persuasive combination that has been assembled around several compounds. DHEA is the one where the definitive experiment was actually run, at a full replacement dose, for two years, against placebo, and reported in a major journal. It found nothing. That result is more useful than another decade of correlational papers, and it is the reason DHEA sits closer to a diagnostic marker than to a therapy for men over 40.

Continue Reading

Related Articles

Guide

Testosterone and Cortisol: The Stress-Performance Tug of War

8 min read

Read Article →

Hormones

SHBG: Why Your Total Testosterone Looks Normal and You Still Feel Flat

12 min read

Read Article →

Longevity

NMN, NR, or an IV Drip: What NAD+ Precursors Actually Do for Men Over 40

13 min read

Read Article →